Padsevonil

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
30
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Elderly Study Participants

Conditions

Elderly Study Participants, Adult Study Participants

Trial Timeline

Jul 9, 2019 โ†’ Oct 3, 2019

About Padsevonil

Padsevonil is a phase 1 stage product being developed by UCB for Elderly Study Participants. The current trial status is completed. This product is registered under clinical trial identifier NCT04013191. Target conditions include Elderly Study Participants, Adult Study Participants.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (5)

NCT IDPhaseStatus
NCT04136444Phase 1Terminated
NCT04075409Phase 1Completed
NCT04013191Phase 1Completed
NCT03370120Phase 2Terminated
NCT03373383Phase 2Completed

Competing Products

15 competing products in Elderly Study Participants

See all competitors
ProductCompanyStageHype Score
YM150 + PlaceboAstellas PharmaPhase 1
33
ASP3325 + PlaceboAstellas PharmaPhase 1
33
E2022 Tape FormulationEisaiPhase 1
33
DonepezilEisaiApproved
85
AZD3293 + PlaceboAstraZenecaPhase 1
33
TC-5214 + PlaceboAstraZenecaPhase 1
33
AZD3293 + PlaceboAstraZenecaPhase 1
33
EsmirtazapineMerckPhase 3
77
Pertuzumab + trastuzumab + Pertuzumab + trastuzumab + metronomic chemotherapyRochePhase 2
52
PF-06648671 + Midazolam + PlaceboPfizerPhase 1
32
PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + PlaceboPfizerPhase 1
32
Vitamin D + Sham Exercise + Vitamin D + ExercisePfizerPhase 1
32
HSK3486 + HSK3486 + HSK3486 + HSK3486Haisco Pharmaceutical GroupPhase 1
30
TD-1439 + PlaceboTheravance BiopharmaPhase 1
28
TD-0714 + PlaceboTheravance BiopharmaPhase 1
28